

Company Announcement

20 April 2009

Novo Nordisk A/S – Share repurchase programme

On 29 January 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.

Since the announcement as of 6 April 2009, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	3,832,041		1,081,993,735
6 April 2009	75,000	247.67	18,575,250
7 April 2009	76,700	251.47	19,287,749
8 April 2009	76,700	246.84	18,932,628
14 April 2009	81,700	238.14	19,456,038
15 April 2009	110,000	237.61	26,137,100
16 April 2009	77,000	243.53	18,751,425
17 April 2009	76,000	252.41	19,183,160
Accumulated under the programme	4,405,141		1,222,317,085

With the transactions stated above, Novo Nordisk owns a total of 29,257,523 treasury shares, corresponding to 4.6% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:

Outside North America:

Elin K Hansen

Tel: (+45) 4442 3450

ekh@novonordisk.com

In North America:

Sean Clements

Tel: (+1) 609 514 8316

secl@novonordisk.com

Investors:

Outside North America:

Mads Veggerby Lausten

Tel: (+45) 4443 7919

mlau@novonordisk.com

Kasper Roseeuw Poulsen

Tel: 4442 4471

krop@novonordisk.com

In North America:

Hans Rommer

Tel: (+1) 609 919 7937

hrrmm@novonordisk.com